Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ef... Read More

Singapore Clinical Trial: A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hypertensive patients.

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hype... Read More

Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascimin... Read More

Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with c... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy ve... Read More

Singapore Clinical Trial: PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2 arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2 arm parallel-group, double-blind, placebo-c... Read More

Singapore Clinical Trial: Bepirovirsen Liver Biopsy study

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Bepirovirsen Liver Biopsy study'. The following are the other relevant details related to the trial:... Read More

Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and... Read More

Singapore Clinical Trial: A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC wh... Read More

Singapore Clinical Trial: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosin... Read More

• ««
• «
• 12585
• 12586
• 12587
• 12588
• 12589
• 12590
• 12591
• 12592
• 12593
• 12594
• »
• »»